
    this study was prematurely discontinued because the program for progressive supranuclear palsy
    was discontinued due to lack of efficacy.
  
['progressive supranuclear palsy (psp)']
['abbv-8e12', 'placebo solution for iv infusion on day 15']

        Inclusion Criteria:

          -  Participant completed the 52-week treatment period in Study M15-562 (NCT02985879)

          -  In the opinion of the investigator, the participant was compliant during participation
             in Study M15-562 (NCT02985879)

          -  Participant has an identified, reliable, study partner (e.g., caregiver, family
             member, social worker, or friend)

        Exclusion Criteria:

          -  Participants who weigh less than 44 kg (97 lbs) at the time of study entry

          -  Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI)

          -  Participant has any significant change in his/her medical condition that could
             interfere with the subject's participation in the study, could place the subject at
             increased risk, or could confound interpretation of study results

          -  More than 8 weeks have elapsed since the participant received his/her last dose of
             study drug in Study M15-562 (NCT02985879)

          -  Participant is considered by the investigator, for any reason, to be an unsuitable
             candidate to receive ABBV-8E12 or the participant is considered by the investigator to
             be unable or unlikely to comply with the dosing schedule or study evaluations
      